Stock Track | Evolus Inc. Stock Soars 5.12% as Q4 Results Impress, Driving Optimism for Growth

Stock Track

2025/01/23

Shares of Evolus Inc. (EOLS) surged 5.12% on Wednesday, outperforming the broader market in an intraday session marked by optimism surrounding the company's impressive preliminary fourth-quarter 2024 performance and promising growth prospects.

The biopharmaceutical company's stock rallied after reporting strong preliminary Q4 2024 results, with sales of $79 million, a 30% year-over-year increase that surpassed expectations. Investors were buoyed by Evolus' robust growth outlook, as the company projects net revenues of $345 million to $355 million in 2025, representing a 30% to 33% growth from 2024.

Additionally, Evolus' upcoming product launches, including FDA approvals for Evolysse Form and Evolysse Smooth, have further fueled investor confidence in the company's ability to sustain its earnings and revenue growth trajectory. With these promising developments, market sentiment surrounding Evolus' prospects has strengthened, driving the stock's upward momentum on Wednesday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1179444417"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179444417\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179444417?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 00:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179444417","market":"us","top_or_hot":-1,"title":"Stock Track | Evolus Inc. Stock Soars 5.12% as Q4 Results Impress, Driving Optimism for Growth","media":"Stock Track","content":"<p>Shares of Evolus Inc. (EOLS) surged 5.12% on Wednesday, outperforming the broader market in an intraday session marked by optimism surrounding the company's impressive preliminary fourth-quarter 2024 performance and promising growth prospects.</p>\n\n<p>The biopharmaceutical company's stock rallied after reporting strong preliminary Q4 2024 results, with sales of $79 million, a 30% year-over-year increase that surpassed expectations. Investors were buoyed by Evolus' robust growth outlook, as the company projects net revenues of $345 million to $355 million in 2025, representing a 30% to 33% growth from 2024.</p>\n\n<p>Additionally, Evolus' upcoming product launches, including FDA approvals for Evolysse Form and Evolysse Smooth, have further fueled investor confidence in the company's ability to sustain its earnings and revenue growth trajectory. With these promising developments, market sentiment surrounding Evolus' prospects has strengthened, driving the stock's upward momentum on Wednesday.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Evolus Inc. Stock Soars 5.12% as Q4 Results Impress, Driving Optimism for Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Evolus Inc. Stock Soars 5.12% as Q4 Results Impress, Driving Optimism for Growth\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-01-23 00:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Evolus Inc. (EOLS) surged 5.12% on Wednesday, outperforming the broader market in an intraday session marked by optimism surrounding the company's impressive preliminary fourth-quarter 2024 performance and promising growth prospects.</p>\n\n<p>The biopharmaceutical company's stock rallied after reporting strong preliminary Q4 2024 results, with sales of $79 million, a 30% year-over-year increase that surpassed expectations. Investors were buoyed by Evolus' robust growth outlook, as the company projects net revenues of $345 million to $355 million in 2025, representing a 30% to 33% growth from 2024.</p>\n\n<p>Additionally, Evolus' upcoming product launches, including FDA approvals for Evolysse Form and Evolysse Smooth, have further fueled investor confidence in the company's ability to sustain its earnings and revenue growth trajectory. With these promising developments, market sentiment surrounding Evolus' prospects has strengthened, driving the stock's upward momentum on Wednesday.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EOLS","symbol_name":"Evolus Inc.","start_time":0,"source_url":"","article_id":"1179444417","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179444417","pubTimestamp":1737561751,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Evolus Inc.  surged 5.12% on Wednesday, outperforming the broader market in an intraday session marked by optimism surrounding the company's impressive preliminary fourth-quarter 2024 performance and promising growth prospects.The biopharmaceutical company's stock rallied after reporting strong preliminary Q4 2024 results, with sales of $79 million, a 30% year-over-year increase that surpassed expectations. Investors were buoyed by Evolus' robust growth outlook, as the company projects","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EOLS":"Evolus Inc."},"translate_title":"股票追踪Evolus Inc.第四季度业绩令人印象深刻，推动增长乐观情绪，股价飙升5.12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EOLS":1},"content_text":"Shares of Evolus Inc. (EOLS) surged 5.12% on Wednesday, outperforming the broader market in an intraday session marked by optimism surrounding the company's impressive preliminary fourth-quarter 2024 performance and promising growth prospects.\nThe biopharmaceutical company's stock rallied after reporting strong preliminary Q4 2024 results, with sales of $79 million, a 30% year-over-year increase that surpassed expectations. Investors were buoyed by Evolus' robust growth outlook, as the company projects net revenues of $345 million to $355 million in 2025, representing a 30% to 33% growth from 2024.\nAdditionally, Evolus' upcoming product launches, including FDA approvals for Evolysse Form and Evolysse Smooth, have further fueled investor confidence in the company's ability to sustain its earnings and revenue growth trajectory. With these promising developments, market sentiment surrounding Evolus' prospects has strengthened, driving the stock's upward momentum on Wednesday.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}